Bendamustine in patients with relapsed or refractory multiple myeloma

por Michael, M, Bruns, I, Bölke, E, Zohren, F, Czibere, A, Safaian, N N, Neumann, F, Haas, R, Kobbe, G, Fenk, R
Publicado 2010

Therapy-related myeloid neoplasms following treatment for multiple myeloma—a single center analysis

por Boquoi, A., Banahan, S. M., Mohring, A., Savickaite, I., Strapatsas, J., Hildebrandt, B., Kobbe, G., Gattermann, N., Haas, R., Schroeder, T., Germing, U., Fenk, R.
Publicado 2022

P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FRO...

por Mai, E. K., Bertsch, U., Fenk, R., Tichy, D., Besemer, B., Dürig, J., Schroers, R., von Metzler, I., Hänel, M., Mann, C., Asemissen, A. M., Heilmeier, B., Nievergall, E., Huhn, S., Kriegsmann, K., Weinhold, N., Luntz, S., Holderrried, T. A. W., Trautmann-Grill, K., Gezer, D., Klaiber-Hakimi, M., Müller, M., Khandanpour, C., Knauf, W., Scheid, C., Munder, M., Geer, T., Riesenberg, H., Thomalla, J., Hoffmann, M., Raab, M. S., Salwender, H. J., Weisel, K. C., Goldschmidt, H.
Publicado 2022